Close
Almac
Achema middle east

Vidacare study reveals IO infusion equivalent to IV in Therapeutic Hypothermia

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Building Resilient Pharma Portfolios in an Era of Scientific and Market Uncertainty

Pharmaceutical companies are radically redesigning portfolio strategies to survive a "triple threat" environment of scientific complexity, regulatory upheaval like the IRA, and capital scarcity. This analysis explores the shift from efficiency-driven models to resilience-first frameworks, detailing how leaders are embedding optionality into pipelines, embracing modality agnosticism, and using dynamic resource allocation to thrive amidst volatility.
- Advertisement -

Vidacare’s study to compare Intraosseous (IO) vascular access to infuse chilled saline as effectively as peripheral intravenous (IV) access to achieve therapeutic hypothermia showed no statistical difference between the two routes.

 

The study was named ‘Infusing Chilled Saline Through the Intraosseous Route is Equivalent to Infusion Through the Intravenous Route in Reducing the Core Temperature in Swine.’

It investigated whether Intraosseous (IO) vascular access may be effectively used to infuse chilled saline to achieve Therapeutic hypothermia (TH) as an alternative to peripheral intravenous (IV) access.

It was observed that IO and IV temperature reductions were statistically equivalent, and concluded no clinical or statistical difference between IV and IO when comparing the two routes for infusion of chilled saline for therapeutic hypothermia.

The research used the EZ-IO Intraosseous Infusion System, a battery-powered device to establish immediate vascular access and the only IO device which is FDA cleared for humeral insertion.

 

Latest stories

Related stories

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Building Resilient Pharma Portfolios in an Era of Scientific and Market Uncertainty

Pharmaceutical companies are radically redesigning portfolio strategies to survive a "triple threat" environment of scientific complexity, regulatory upheaval like the IRA, and capital scarcity. This analysis explores the shift from efficiency-driven models to resilience-first frameworks, detailing how leaders are embedding optionality into pipelines, embracing modality agnosticism, and using dynamic resource allocation to thrive amidst volatility.

New data from Elsevier finds one in three corporate researchers have not yet used AI at work

AI tools are boosting productivity, but researchers raise concerns...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »